Clinical Trials in New York

Showing 16021-16040 of 22,668 trials

Extension Study of Gelesis100 on Body Weight

NCT03021291

This study is designed to assess the effect of Gelesis100 on body weight after an additional exposure of 24 weeks in subjects who completed the 24-week treatment period, and had at least 3% weight loss, in the Gelesis Loss Of Weight GLOW, NCT02307279) study.

Overweight and Obesity

Gelesis, Inc.36 participantsStarted Jan 2017

San Diego, California, United States • Tustin, California, United States • Aurora, Colorado, United States +13 more locations

COMPLETEDPhase 3< 1 mile

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

NCT00088179

During a heart bypass procedure, a substance called "complement" is activated by the body. This "complement activation" causes an inflammatory response that can lead to side affects such as chest pain, heart attacks, stroke, heart failure, or death. The purpose of this study is to find out if the study drug (pexelizumab), that blocks "complement activation," can reduce such side effects and be given safely to patients requiring the bypass procedure with the use of the heart-lung machine.

Coronary Artery Disease

Alexion Pharmaceuticals, Inc.4,000 participantsStarted Jul 2004

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +185 more locations

Extension Study of Gelesis100 on Body Weight

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Find Trials by Condition in New York

Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)

A Study of LY2801653 in Advanced Cancer

Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer

Study of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Comparing VERSAJET With Conventional Surgical Procedures in the Removal of Unhealthy Tissue From Lower Limb Ulcers

Evaluation of CHAM JAM Increasing Physical Activity Levels in Students

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Medications for Chronic HIV: Education and Collaboration

PK and PD Study of Oral F/TAF for HIV Prevention

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer